FDA reviewers support Celltrion's biosimilar Remicade

(Reuters) - U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news